Spec Script Sales 2026: Which Genres Are Actually Selling

Spec Script Sales 2026: A Market Snapshot

Anyone researching spec script sales 2026 hits the same wall within about ten minutes: there is no public, audited tally of how many original screenplays have sold industry wide this year. The trades report deals one at a time. Independent trackers count what they can see from the outside. Nobody publishes a verified total. So an honest snapshot has to be assembled from three things that can actually be checked: the long trend line, the individual sales that made print, and the union contract that sets the floor under all of them.

Start with the trend line, because it calibrates everything else. Industry figures cited in trade press put roughly 173 spec deals in 1995 against about 62 in 2017. That is a market that shed nearly two thirds of its volume in a generation, and the slide continued after that. The most recent independently sourced running count anywhere in the public record comes from screenwriter and tracker Scott Myers, reported by No Film School in August 2025: 8 spec sales in that month alone, 19 for the year to date, against 14 by the same point in 2024 and just 11 for the whole of 2023. Myers noted the monthly pace had not been matched since March 2017.

The shape of those numbers matters more than any single one of them. Eleven sales across a full calendar year is a market on life support. Nineteen by August of the following year is a market with a pulse again. What does not exist is an equivalent 2026 running total from a source you can check, and you should treat any article that hands you one with suspicion.

What 2026 does offer is deal by deal evidence, and there has been a steady drip of it. Sony, Paramount, Netflix, New Regency, Screen Gems, FilmNation and Chernin Entertainment all closed on original specs during the year, across period action drama, thriller, espionage, comedy, action comedy and romantic comedy. Almost none of those deals came with a disclosed price, which is normal, and which is the single biggest limitation on reading this market accurately.

Screenwriter Cole Haddon, writing in January 2026, described the commercial spec market as "resurrected." The characterisation of what was actually moving, scripts with a clear premise, a working genre engine and escalating stakes, is Black List founder Franklin Leonard's, quoted in that piece. That is attributed opinion rather than a data point, but it lines up with the genre distribution of the deals that followed it.

Which Genres Are Actually Selling Right Now

The most granular public read on buyer attention in 2026 comes from ScriptMatch.ai's buyer signal index, pulled on May 26, 2026. Its year to date genre totals: Drama 3,107 signals through April, Documentary 1,924, Thriller 1,206 through May 26, Comedy 1,119 through May and Horror 1,081.

Before building anything on those numbers, read the methodology, which the source states plainly: a signal measures trade press presence, not a count of executed deals. The index is compiled from articles in Variety, The Hollywood Reporter, Deadline, IndieWire, Screen International, TheWrap and festival wire services. It also covers slightly different windows per genre, so the totals are not strictly comparable to each other. What it measures is how loudly a genre is being discussed in the trades, which correlates with buyer activity without being the same thing.

With that caveat in place, the useful read for a spec writer: drama dominates coverage volume, which it almost always does, because drama absorbs festival reporting, awards positioning and prestige packaging alongside actual acquisitions. Documentary's position reflects a market that runs on trade coverage of festival premieres and acquisitions rather than on spec screenplays at all. Strip those two out and thriller, comedy and horror sit within a few hundred signals of each other. Three genres, comparable attention, and all three are genres a solo writer can execute without a production budget on the page.

That clustering is the practical answer to which genres are selling screenplays now. Not because signal volume equals a sale, but because a script has to be read before it can be bought, and readers look hardest where their employers are already shopping.

Getting read remains the actual bottleneck. Alongside agency representation, contests and the Black List, script marketplaces such as ScriptLix are one more channel unrepped writers use to put finished material in front of readers, which matters most in exactly the genres where buyer attention is already concentrated.

The genre with the widest gap between coverage and closed deals is comedy. It sits mid pack in signal volume yet accounts for more named 2026 spec sales than any other category in the reporting further down this page. Coverage indices undercount comedy for a structural reason: comedy deals rarely arrive with festival premieres or awards campaigns attached, so they generate one story and then go quiet.

Why Horror and Thriller Specs Are Back in Demand

The commercial case buyers make internally is short, and it is made of two 2025 titles. Sinners, an original screenplay directed by Ryan Coogler for Warner Bros., grossed $279,989,632 domestically and $370,289,632 worldwide. Weapons, written and directed by Zach Cregger, also for Warner Bros., grossed $151,572,492 domestically and $270,072,492 worldwide. Neither was a sequel, a remake or an adaptation of a known property.

Trade press framed both as rare studio bets on original horror material that paid off, and tied that outcome to renewed buyer appetite for spec horror and thriller scripts. Be careful how far you extend the claim. Published figures for horror's share of the total domestic box office vary widely depending on the data provider and the measurement window, so the defensible statement is about these two films and the behaviour they encouraged, not about a genre wide share number you can quote.

The buyer side of thriller is where the 2026 data gets specific. By year to date signal volume, the most active thriller buyers tracked were Lionsgate (153), Apple TV+ (104), Shudder (43), Apple corporate entities (40), Black Bear (29), Warner Bros. Pictures (26), Bleecker Street (21), AMC (21), Charades (20) and Fifth Season (20).

Two things in that list deserve a spec writer's attention. First, the spread: a studio, a streamer, a genre focused subscription service, two specialty distributors and a production and finance company all appear near the top, which means a thriller spec has more than one kind of home. Second, seven of the twenty most active thriller buyers are international sales agents and distributors, including Charades, Showbox, Beta Cinema, Latido Films and Pathe. That is a structural fact about how thrillers get financed. A contained thriller with a legible logline presells territories, and a buyer who can presell has a reason to move on material that a domestic only buyer would pass on.

Horror benefits from the same arithmetic with a lower budget floor. That is why the two genres keep appearing in the same sentence in acquisition conversations, and why a writer choosing between projects on limited time should weight the one that can be produced without tentpole money behind it.

Inside the 2025 Black List and What It Signals to Buyers

The 2025 Black List, the 21st annual edition and still the current one, was published on December 9, 2025. It comprises 74 unproduced screenplays by 86 writers, chosen from ballots submitted by close to 500 film executives, each naming up to ten favorite feature scripts of the year.

The top five by mention count: "Best Seller" by Matisse Haddad, a literary and erotic thriller drama, at 48 mentions; "Equity" by Ward Kamel at 35; "Rush" by Read Masino and Cassidy Alla at 34; "Untouchable" by Julian Silver and Reiss Clauson-Wolf at 30; and "Minnow" by Zach Strauss and Chris Silber at 27.

Black List founder Franklin Leonard characterized the 2025 crop as "preoccupied with what happens when the systems we live in, economic, political, algorithmic, stop working the way they're supposed to." That is arguably the most actionable sentence a spec writer will read about the current market, because it is a thematic read from the one person looking at the aggregate ballot.

Two clarifications, because the list gets misread constantly. It is a survey of executive enthusiasm for unproduced material, not a sales chart: a script's position tells you how many executives liked it enough to name it, not what it sold for or whether it sold at all. And it is compiled from what executives already have in their inboxes, which means placement is downstream of circulation.

The track record is why it still carries weight. Since the survey began in 2005, more than 1,000 screenplays have appeared on it. At least 450 have been produced as theatrical films, together grossing over $30 billion and collecting a few hundred Academy Award nominations. Trade coverage tied to the survey's twentieth anniversary puts the tally at 273 nominations and 54 wins, above the 241 and 50 that older write ups still repeat.

For a working writer the takeaway is narrower than "get on the Black List." It is that the material executives champion in a given year tends to share a preoccupation, and the 2025 preoccupation was institutional failure. Writing toward that is not chasing a trend, it is aligning with what the people reading your script are currently responding to.

Named Deals: What Studios and Streamers Bought in 2026

Individual sales are the only hard evidence of this market, so here is what made print, with one standing caveat: in nearly every case the price was not disclosed in available reporting, and where a figure has circulated it has done so in headline summaries rather than in verifiable copy. Treat any specific dollar amount attached to these titles as unconfirmed.

The Ballad of the Ember Knight, a period action drama set during the Hundred Years' War by sibling writers Kieran and Brennan O'Dea, was preempted by Sony in August 2026 with nobody attached to produce, shopped by the writers' management company Kaplan/Perrone Entertainment. A period action spec selling to a studio is the outlier in this list, and worth noting for exactly that reason.

Panic Officer, an espionage thriller by Ben Ripley, sold to New Regency in February 2026. Sweet Spot, a thriller, went to Paramount's Primal banner in July 2026.

White Knight, a high concept R rated comedy by Christopher William Young, was acquired by Screen Gems in February 2026. Ram, an action comedy by Chris Bremner, sold to Netflix in April 2026. I'd Like to Speak to Your Manager, an absurdist action thriller by Gabe Delahaye, sold to FilmNation in June 2026. Just ahead of the window, in November 2025, Aunt Roxie, a comedy by Johnny Rosenthal, sold to Netflix with Ryan Reynolds' Maximum Effort producing.

One Month Mark, a romantic comedy, was landed by Chernin Entertainment and by June 2026 was set up at Apple with Jennifer Lawrence attached to star. That progression is instructive on its own: the sale and the packaging are separate events, weeks or months apart, and the second one generates the bigger headline.

Count the genres and the pattern is hard to miss. Comedy in its various forms accounts for the largest share of named spec sales here, thriller and espionage follow, and period action is the single exception. Which is a useful corrective to the signal index: drama leads coverage volume, comedy leads this particular list of closed original screenplay deals. Both readings are accurate, they simply measure different things.

The WGA's New Minimums and What They Mean for Spec Writers

The contract in force is the 2026 WGA Theatrical and Television Basic Agreement, which took effect on May 2, 2026 and runs through May 1, 2030, superseding the 2023 MBA. Members ratified it on April 24, 2026 with 90.38% in favor, 4,282 votes to 456.

On compensation, general minimums rise 1.5% in year one, effective May 2, 2026, then 3% in each of years two, three and four, on May 2 of 2027, 2028 and 2029. Those compound rather than simply add, so the real increase is roughly 10.9% across the four year term. The Guild publishes no cumulative figure of its own, and the 10.5% that circulates is a simple sum. The Guild Health Plan employer contribution rate rises 3.25 percentage points to 16.25% of covered earnings effective May 2, 2026, then to 16.75% from May 2, 2027.

Now the part that requires care, because the open web is full of confident wrong answers. The one theatrical dollar minimum published with a confirmed 2026 to 2027 effective date is for a page one rewrite of an existing screenplay: $57,500 for a high budget feature and $31,500 for a low budget feature, effective May 2, 2026. That is a rewrite minimum. It is not the minimum for purchasing an original spec screenplay, and it should never be quoted as one.

Search for the guild minimum on an original screenplay purchase and you will find figures presented as current that are in fact derived from rates several MBA cycles old. Those numbers predate two contracts. Quoting them in a negotiation, or setting your expectations by them, anchors you to a rate that no longer exists. Pull the current schedule from wga.org, or have your representative do it, and check the effective date printed on the document itself.

Two further practicalities. A minimum is a floor, not a market price; every named sale above was negotiated by a representative, and the distance between floor and price is the entire job. And the health contribution increase is genuine compensation even though it never makes a headline: a covered sale in 2027 carries a materially larger employer contribution than the same sale would have carried in early 2026.

How to Read a Spec Script Sales 2026 Deal Report

Trade reporting on spec sales is written in a compressed dialect. Decoding it correctly is the difference between usable market intelligence and a distorted picture of your own odds.

"Sold to" means an executed purchase, and "acquired" means the same thing. "Set up at" usually means a project moved to a buyer with elements already attached, which is not the same event as the original sale. "Preempt" means a buyer moved before a wide submission closed, which signals competitive heat and usually a stronger price, though not one you can quantify without disclosure.

Attachments arrive on their own schedule. A romantic comedy landing at a production company in one month and reappearing weeks later with a star attached at a streamer is one project generating two headlines, and only the first was a spec sale.

Price silence is the default, not a red flag. Among the 2026 deals above, essentially none carried a confirmed public figure. Phrases like "near seven figures" frequently circulate in search summaries without appearing in the article behind them, so treat them as rumor unless you can read the sentence in its original context.

Signal indices are not deal counts. A genre with three thousand signals may have produced fewer executed spec purchases than a genre with a thousand, because coverage volume rewards festivals, awards runs and packaging news. Ask what any index actually counts before you weight it.

Year end lists are not sales either. Every script on the 2025 Black List was unproduced at publication, and many were unsold.

Finally, watch the buyer rather than the number. Whether an espionage thriller went to a studio, a streamer, a specialty distributor or a company that finances through international presales tells you far more about who to target next than an undisclosed price ever would.

What Comes Next for Spec Script Sales 2026

The remainder of the cycle has a known calendar. The next general minimum increase, 3%, lands on May 2, 2027, alongside the health contribution rise to 16.75%. Another Black List edition will follow the 2025 one, which published in December 2025. And the trades will keep reporting sales one at a time, with no aggregate anyone can audit.

What that means for the next six months of your writing time is fairly concrete. The genres with demonstrable buyer attention are thriller, comedy and horror, clustered closely in signal volume, and the named deals skew comedy and thriller. Original horror has two 2025 commercial results behind it that buyers cite without prompting. Thriller has a financing structure, with international sales agents making up a meaningful share of the most active buyers, that gives a contained script more than one route to a yes.

On the page, the two most credible pieces of guidance available point in the same direction. Leonard's read is that a clear premise, a genre engine and escalating stakes are what moved. Leonard's read of the 2025 ballot is that executives gravitated toward stories about systems, economic, political and algorithmic, failing to work as intended. A contained thriller or horror script built on institutional failure with a legible engine sits at the intersection of both, which is less a formula than a description of where attention currently is.

The market that produced 173 deals in 1995 is not coming back. The one that recorded 11 sales in a full calendar year is, on the most recent evidence available, also behind us. What exists now is smaller, more genre specific and more legible than either, and it rewards the writers who finish, who choose a genre with buyers who are visibly active, and who stop waiting for a tally nobody publishes.